Caligor Opco, which specializes in global comparator sourcing, early access to medicines and drug life-cycle management, has named two pharmaceutical executives to its Clinical Trial Services (CTS) business unit. Andrea Chopek has been appointed global head of Business Development for CTS. Craig LaMarca has been named global head of Business Development for TrialAssist, a business line under CTS. Both positions are new for the company, which recently expanded its international operations with the opening of a state-of-the-art, 33,000-square-foot facility in the UK.

“Andrea and Craig are energetic, accomplished leaders who have demonstrated a track record of success in the pharmaceutical industry,” said Caligor CEO Tammy Bishop. “We welcome them to the Caligor team and look forward to capitalizing on their business development skills and sales expertise as we continue to build out our CTS capabilities and further expand the business. With the expansion of our operations in the U.K., we are expertly positioned to meet growing demand for our clinical trial supply services, from commercial medicine procurement to customized packaging, labeling and distribution solutions in support of clinical studies worldwide.”

Chopek served as a U.S. Navy Lieutenant on the nuclear-powered aircraft carrier USS NIMIZ (CVN-68) in supply, expediting, procurement and logistics. She brings nearly 20 years of experience in senior positions within the biopharmaceutical industry, focusing on pharmaceutical development and clinical trial supply. She joined the company from Clinigen, where she worked most recently as U.S. head of Business Development, Clinical Trial Services. 

Before he joined Caligor, LaMarca served as a business development executive for PCI Pharma Services, an international pharmaceutical services provider. From 2013 to 2015, he was the North American Business Development director for NextPharma, a pharmaceutical contract development and manufacturing organization. LaMarca has also served in business development roles for Cytovance Biologics and ALPCO (American Laboratory Products Company).

Caligor Opco, a portfolio company of Diversis Capital, is a global company that manages the regulatory, logistics and supply chain needs for global access programs as well as the sourcing, storing and distribution of commercial medicines, medical devices and ancillary supplies for clinical trials. Caligor’s global access programs help to meet the medical needs of patients worldwide by providing access to unlicensed/unapproved medicines in situations where the drug has not yet been approved, or is otherwise commercially unavailable.